0718 (0718) Fair Value & Analysis

Healthcare · Market cap HK$168M

0 0718 0718 · HK

PriceHK$0.0320

Fair ValueHK$0.0474

Upside+48.0%

Quality49/100

Evidence: Low Range HK$0.0378 – HK$0.0634

Fair value as of: Jul 2, 2026

From 7 valuation models · updated today

Price vs Fair Value (12 months)

12‑month range HK$0.0290 – HK$0.0650 · fair‑value band HK$0.0378 – HK$0.0634 · the HK$0.0320 price screens below the HK$0.0474 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0718 (0718) currently trades at HK$0.0320, while our model-based Fair Value estimate is HK$0.0474 — implying the stock looks roughly 48.0% undervalued today. We read business quality at 49/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Trailing-twelve-month revenue stands at HK$126M. Revenue grew 24.8% year over year. Net debt stands at HK$1.4B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$126M

Revenue growth (YoY) +24.8%

Net margin -294%

Return on equity -398%

Free cash flow HK$19.4M FY2025

Operating margin 16.7%

More key figures

EPS (TTM) HK$-0.0400

Net debt HK$1.4B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0718 reported revenue of HK$125M in FY2025 versus HK$309M in FY2021, a compound −20.2%/yr. Reported net income was −HK$372M in FY2025.

Revenue −20.2%/yr

FY21 HK$309M

FY22 HK$160M

FY23 HK$212M

FY24 HK$122M

FY25 HK$125M

Net income

FY21 −HK$441M

FY22 −HK$1.5B

FY23 −HK$1.2B

FY24 −HK$760M

FY25 −HK$372M

Is 0718 fairly valued? → Check now

Similar stocks

6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
McKesson Corporation M1CK34	R$990.72	R$188.90	-81%
Cencora, Inc C1CO34	R$709.32	R$400.70	-44%
Cardinal Health, Inc CAH	$228.91	$141.77	-38%
Sigma Healthcare Limited SIGGF	$2.35	$0.7800	-67%
Sitka Gold Corp SIG	A$2.76	A$0.3300	-88%
Shanghai Pharmaceuticals Holding 601607	¥16.34	¥34.72	+112%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0718 (0718) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.0474 versus a price of HK$0.0320 — about +48% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 0718?

Our model-based fair value for 0718 is HK$0.0474 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.0320.

What is the quality score of 0718?

0718 has a Quality Score of 49/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0718 (0718)?

0718 reported trailing-twelve-month revenue of about HK$126M (latest available figure, as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.